Frequently Asked Questions

View Options View as Grid View as List
  • Expand Icon How many doses of Trulicity are available?

    Trulicity offers two efficacious doses.1 The recommended starting dosage of Trulicity is 0.75 mg once a week. For patients requiring additional glycemic control, the dosage may be increased to 1.5 mg per week.

  • Expand Icon Can Trulicity be used in combination with basal insulin?

    Basal insulin can be titrated as needed and combined with either dose of once-weekly Trulicity.1

    Select Important Safety Information:

    The risk of hypoglycemia is increased when Trulicity is used in combination with insulin secretagogues (eg, sulfonylureas) or insulin. Patients may require a lower dose of sulfonylurea or insulin to reduce the risk of hypoglycemia.

    See the A1C reduction Trulicity provided in combination with basal insulin.

  • Expand Icon How should the Trulicity Pen be stored and handled?

    • Store the Trulicity Pen in the refrigerator between 36°F to 46°F (2°C to 8°C)2
    • The Trulicity Pen may be stored at room temperature below 86°F (30°C) for up to a total of 14 days2
    • Do not freeze the Trulicity Pen. If the pen has been frozen, throw the pen away and use a new pen2
    • Storage of the Trulicity Pen in the original carton is recommended. Protect the pen from direct heat and light2
    • The pen has glass parts. Handle it carefully. If the pen is dropped on a hard surface, do not use it. Use a new pen for the injection2
    • Keep the Trulicity Pen and all medicines out of the reach of children2
  • Expand Icon Did patients on Trulicity lose weight in clinical trials?

    Trulicity is not a weight loss drug. While many people in clinical trials lost weight, some did gain weight.

    In clinical studies, weight change was a secondary endpoint. Mean weight change was -1.1 lb to -6.8 lb at the 1.5 mg dose and +0.4 lb to -6.0 lb at the 0.75 mg dose.1,3

  • Expand Icon Has Trulicity been studied in older patients?

    Yes. In pooled study results, there were no overall differences in safety or efficacy between older and younger patients but greater sensitivity in some older individuals cannot be ruled out.1

    • 620 (18.6%) Trulicity-treated patients were 65 years of age or over
    • 65 (1.9%) Trulicity-treated patients were 75 years of age and over
  • Expand Icon What is the half-life of Trulicity?

    Once-weekly Trulicity has a plasma half-life of approximately 5 days.1

  • Expand Icon How do I write Trulicity?

    Prescription pads for Trulicity 0.75 mg and 1.5 mg

    The amount to be dispensed may be written as “1 box” or “4 pens.”

  • Expand Icon What happens if a patient misses a dose?

    If a dose is missed, instruct patients to administer as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. If less than 3 days remain before the next scheduled dose, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.1

  • Expand Icon How was the Trulicity molecule designed?

    The Trulicity molecule was designed with patients in mind

    • Prolong incretin activity to enable once‑weekly administration
      • Amino acid substitution on human GLP‑1 protects against DPP‑4 degradation4‑7
      • Increasing the size of the molecule decreases renal clearance and extends the time‑action profile5
    • Eliminate the need for reconstitution
      • Another amino acid substitution on human GLP‑1 and fusion to the modified Fc portion of IgG4 improves solubility4‑7
    Illustration of Trulicity molecule w/captions
  • Expand Icon Did patients on Trulicity lose weight in clinical trials?

    Trulicity is not a weight loss drug. While many people in clinical trials lost weight, some did gain weight.

    In clinical studies, weight change was a secondary endpoint. Mean weight change was -1.1 lb to -6.8 lb at the 1.5 mg dose and +0.4 lb to -6.0 lb at the 0.75 mg dose.1,3

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Back to top